Title: Comparison of DPP-4 Inhibitors.
Authors: Nam Hoon Kim; Sin Gon Kim
Abstract: During past several years, a novel class of antihyperglycemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, has become one of the most important options in the management of type 2 diabetes. These agents have unique insulinotropic actions as well as other advantages such as lower hypoglycemia and a weight-neutral effect compared to traditional insulin secretagogues. To date, 6 different DPP-4 inhibitors have been introduced: sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin and gemiglitin. This review provides a summary of the clinical data for each DPP-4 inhibitor, and discusses the similarities and differences between them
Subjects: CD26 antigen; TYPE 2 diabetes; HYPOGLYCEMIA; SITAGLIPTIN; INCRETINS
Publication: Journal of Korean Diabetes, 2013, Vol 14, Issue 3, p111
ISSN: 2233-7431
Publication type: Academic Journal
DOI: 10.4093/jkd.2013.14.3.111

Comparison of DPP-4 Inhibitors.

Nam Hoon Kim; Sin Gon Kim